Anti-Suicide Drugs Market to Surpass US$ 4.8 Billion by 2024

Monday, March 20, 2017 General News
Email Print This Page Comment bookmark
Font : A-A+

The Global Anti-suicide Drugs Market was valued at US$ 3318.3 million in 2015 and is projected to expand at a CAGR of 4.2% during the forecast period (2016–2024) as highlighted in a new report published by Coherent Market Insights. Introduction of novel
approved drugs expected to be commercialized post-2020 intended for treatment of suicidal ideation would be a major breakthrough for the global anti-suicide drugs market. Until recently suicidal ideation has been treated with anti-depressants anti-anxiety
and anti-psychotic drugs. The trend would continue until the expected launch of Cyclurad by NeruoRx Pharma during the latter half of the forecast period (2016–2024). Cyclurad is a combination of D-cycloserine and Lurasidone and indicated for Acute Suicidal Ideation/Behavior (ASIB) in Bipolar Depression. Other drug candidates are also in the pipeline intended for treatment of suicidal ideation in major depressive disorder (MDD). Suicide is among the major economic burdens to the global economy. According to the World Health Organization (WHO) over 800000 people commit suicide every year. Most of the suicidal deaths occur in Asia Africa and Eastern Europe. Moreover many suicidal attempts go unnoticed until and seldom are reported to suicidal prevention organizations who can help alleviate the issue. Stop Suicide Yellow Ribbon Suicide Prevention Program and American Foundation for Suicide Prevention are some of the leading organizations working for preventing suicides. High prevalence of suicidal attempts and deaths would be another stimulus besides the introduction of novel drugs for the growth of anti-suicide drugs market. N-Methyl-D-aspartate receptor (NMDAR) agonists and antagonist are the prospective candidate for treating suicidal ideation. Companies banking on anti-depressants and anti-psychotic drugs for treating patients at risk for suicide should reconsider their strategy considering these are not very effective at addressing the issue. Nonetheless these drug class are not approved for use in treating patients at risk for suicide. The global anti-suicide drugs market has been driven majorly by off-label recommendations and prescriptions of anti-depressants anti-anxiety and anti-psychotic drugs. Inadequate reach of healthcare facilities and affordable medications is hindering growth of overall healthcare market in emerging economies such as India China Brazil and Indonesia. Therefore companies introducing novel anti-suicidal drugs would be facing a challenge in market penetration in these nations and would be able to capture only a part of these markets to capitalize on the lucrative growth opportunities in these regions. North America and Europe remain potential markets at initial stages for the anti-suicidal drugs. High suicidal rates and accessibility to better medical therapies would be the major contributing factors for the anti-suicide drugs market in these regions. Key takeaways of the market: The global anti-suicide drugs market is majorly characterized by the use of anti-depressants anti-anxiety and anti-psychotic drugs The global anti-suicide drugs market is expected to expand at a CAGR of 4.2% during the forecast period (2016–2024). Rising incidence of suicides across the globe is expected to favor the market growth for anti-suicide drugs over the forecast period. Suicidal rates are higher in Asia Eastern Europe and Africa regions The antibiotic analog (NMDA agonist) segment in the global anti-suicide drugs market is estimated to be growing faster post its FDA approval and commercialization Market growth for anti-depressants and anti-anxiety drugs is projected to be impacted negatively by the launch of FDA approved anti-suicidal drugs expected towards the latter-half of the forecast period Some of the major players present in the global anti-suicide drugs market are Pfizer Inc. AstraZeneca plc Eli Lilly and Company Allergan plc GlaxoSmithKline plc Merck & Co. Inc. H. Lundbeck A/S NeuroRx Inc. and Johnson & Johnson.

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store